Caligan Partners LP 的 Form 4 申報
Standard Biotools Inc.LAB，2022/5/2 申報
- 申報編號
- 0000902664-22-002740
- 申報時間
- 2022/5/2 19:44 ET
- 交易日
- 2022/4/28-5/2
- 申報延遲
- 4 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 3 筆非衍生性交易。公開市場買進合計 $107.6 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Caligan Partners LPCIK 0001727492 | 持股 10% 以上大股東 |
| Johnson David EdwardCIK 0001785557 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Price is the volume weighted average selling price of all sales by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $2.37 to $2.44.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $2.57 to $2.70.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $ 2.71 to $2.89.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.
表 I 有 3 筆交易的價格引用這則附註。
備註
The Persons disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of his or its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that any of the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 or for any other purpose.